Current immunotherapeutic strategies in lung cancer.
New treatment modalities, such as immunotherapeutic strategies, may help improve the currently poor prognosis and outcome of patients suffering from lung cancer. However, thus far, lung cancer has not been considered an immune-sensitive malignancy. Now, there is increasing evidence that specific humeral and cellular anti-tumor immune responses can be evoked. This article reviews immunotherapeutic strategies that are already in clinical use or well-progressed in early clinical trials. A special focus is put on non-small cell lung cancer as the most frequent type of all lung cancers.
Rüttinger
Dominik
D
Department of Surgery, Laboratory of Clinical and Experimental Tumor Immunology, Grosshadern Medical Center, Ludwig-Maximilians-University Munich, Marchioninistrasse 15, 81377 Munich, Germany. dominik.ruettinger@med.uni-muenchen.de
Hatz
Rudolf A
RA
Jauch
Karl-Walter
KW
Fox
Bernard A
BA
D000906:Antibodies / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008954:Models, Biological; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000906:Antibodies; D019496:Cancer Vaccines; D020794:Receptor Protein-Tyrosine Kinases